This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar 1;4(3):333-334.

doi: 10.1001/jamaoncol.2017.4339.

Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?

Lowell E Schnipper¹, Richard L Schilsky²

Affiliations

Affiliations

¹ Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
² American Society of Clinical Oncology, Alexandria, Virginia.

PMID: 29285543
DOI: 10.1001/jamaoncol.2017.4339

Comment

Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?

Lowell E Schnipper et al. JAMA Oncol. 2018.

. 2018 Mar 1;4(3):333-334.

doi: 10.1001/jamaoncol.2017.4339.

Authors

Lowell E Schnipper¹, Richard L Schilsky²

Affiliations

¹ Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
² American Society of Clinical Oncology, Alexandria, Virginia.

PMID: 29285543
DOI: 10.1001/jamaoncol.2017.4339

No abstract available

PubMed Disclaimer

Comment on

Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA. Ben-Aharon O, et al. JAMA Oncol. 2018 Mar 1;4(3):326-332. doi: 10.1001/jamaoncol.2017.4445. JAMA Oncol. 2018. PMID: 29285547 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations